Hikma Pharmaceuticals PLC is a fast growing multinational pharmaceutical group which was founded in 1978 in Jordan. Hikma develops, manufactures and markets a broad range of both branded and non-branded generic and in-licensed products. Hikma is committed to the highest quality manufacturing with multiple FDA approved facilities. Hikma operates in the US, Europe and across the MENA region. Growth in MENA is driven by strong demographics and growing investment in healthcare. Hikma is the fourth listed pharmaceutical company in the FTSE 250. Operations are in 27 manufacturing facilities in 11 countries – FDA approved facilities in 5 countries with cost effective R&D and manufacturing. Their strategy for growth is to strengthen their leading position in the MENA region, develop their global product range in growing therapeutic areas, extend their reach and diversity as partner of choice in the MENA region, increase the scale of their specialty injectables business, leverage their expertise and capacity in the US market, build on their world-class manufacturing and API sourcing capabilities.